Company Profile

Cylex Inc (AKA: Biotechnology Transfer Inc)
Profile last edited on: 5/2/2019      CAGE: 02MW0      UEI:

Business Identifier: FDA-cleared cellular assay of immune system function
Year Founded
1992
First Award
1994
Latest Award
1995
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

8980-I Old Annapolis Road
Columbia, MD 21045
   (410) 964-0236
   contact@cylex.net
   www.cylex.net
Location: Single
Congr. District: 03
County: Howard

Public Profile

In February 2013, a near-bankrupt Cylex Inc was acquired by Viracor-IBT Laboratories Inc, a fellow SBIR recipient. Originally known as Biotechnology Transfer, Inc. (BTI), at that time, Cylex provided consulting and contract research services to industry and academia. Cylex® had been a life science company manufacturing and developing patented in vitro diagnostic products for the assessment of immunity. Products were of value to physicians treating life-threatening diseases or conditions who sought to optimize therapy through individualized management of a patient’s immune system: reducing side effects, improving clinical response and quality of life. ImmuKnow™ - the Cylex® Immune Cell Function Assay - intended to be used as an adjunct to post-transplantation drug level monitoring along with other clinical indicators. Cylex’s patented platform technology also was designed to provide an innovative approach for measuring immune activity in AIDS and cancer patients, and those with infectious diseases, autoimmune or other immune system disorders. In early 2002, Cylex® received FDA clearance for ImmuKnow™ - the Cylex® Immune Cell Function Assay. The assay is used for the detection of cell-mediated immunity in an immunosuppressed population. Cylex has developed and patented a blood test for the measurement of immunity. In vitro CMI can be used to assess the efficacy of therapy used in the treatment of infectious diseases such as HIV and hepatitis, cancer, autoimmunity and transplantation.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1995 1 Army $69,929
Project Title: Rapid Assay of Cellular Immunity in Q Fever
1995 1 NIH $99,999
Project Title: Biotinylated Derivatives Of K+ Channel Toxins
1994 1 NSF $65,000
Project Title: Insect Larvae as Natural Factories for Production of Recombinant Proteins

Key People / Management

  Timothy Ellis -- President

  Marie Dominique Ashen

  Judith Britz -- Chairman and Chief Executive Officer

  Douglas Brown -- CFO, Financial Officer

  Lucy Carruth -- Director of Product Development

  Richard Kowalski -- Director of New Market Development

  Cindy McGiffin

  Marjorie L Wier

Company News

There are no news available.